×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OTLK – outlook therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OTLK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/19
09:00 am
otlk
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
Low
Report
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
2/18
08:13 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock.
2/18
08:13 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $1.00 price target on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $1.00 price target on the stock.
2/17
08:05 am
otlk
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
High
Report
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2/11
08:45 am
otlk
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
Medium
Report
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
1/6
08:35 am
otlk
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
Low
Report
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
1/5
08:33 am
otlk
Oncobiologics (NASDAQ:OTLK) had its price target lowered by analysts at Chardan Capital from $3.00 to $1.00. They now have a "neutral" rating on the stock.
High
Report
Oncobiologics (NASDAQ:OTLK) had its price target lowered by analysts at Chardan Capital from $3.00 to $1.00. They now have a "neutral" rating on the stock.
1/3
01:08 am
otlk
Oncobiologics (NASDAQ:OTLK) was downgraded by analysts at Wall Street Ze
High
Report
Oncobiologics (NASDAQ:OTLK) was downgraded by analysts at Wall Street Ze
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/18
05:01 pm
otlk
Form 8-K Outlook Therapeutics, For: Feb 18
Medium
Report
Form 8-K Outlook Therapeutics, For: Feb 18
2/17
05:01 pm
otlk
Form 10-Q Outlook Therapeutics, For: Dec 31
Medium
Report
Form 10-Q Outlook Therapeutics, For: Dec 31
2/17
08:30 am
otlk
Form 8-K Outlook Therapeutics, For: Feb 17
Medium
Report
Form 8-K Outlook Therapeutics, For: Feb 17
2/11
05:01 pm
otlk
Form 8-K Outlook Therapeutics, For: Feb 11
Medium
Report
Form 8-K Outlook Therapeutics, For: Feb 11
2/5
11:49 am
otlk
Form SCHEDULE 13G/A Outlook Therapeutics, Filed by: SPHERA FUNDS MANAGEMENT LTD.
Medium
Report
Form SCHEDULE 13G/A Outlook Therapeutics, Filed by: SPHERA FUNDS MANAGEMENT LTD.
1/26
05:03 pm
otlk
Form ARS Outlook Therapeutics, For: Sep 30
Medium
Report
Form ARS Outlook Therapeutics, For: Sep 30
1/26
05:02 pm
otlk
Form DEFA14A Outlook Therapeutics,
Medium
Report
Form DEFA14A Outlook Therapeutics,
1/26
05:01 pm
otlk
Form DEF 14A Outlook Therapeutics, For: Mar 10
Medium
Report
Form DEF 14A Outlook Therapeutics, For: Mar 10
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/15
Form 10-Q Outlook Therapeutics, For: Mar 31
62.8%
12/31 Form 4 Outlook Therapeutics, For: Dec 31 Filed by: Pillai Arun Kumar 48.6%
2/24 Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market 20.0%
12/3 Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 16.9%
7/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 14.8%
12/30 Form 4 Outlook Therapeutics, For: Dec 23 Filed by: Pillai Arun Kumar 13.5%
12/23 Form 8-K Outlook Therapeutics, For: Dec 20 11.3%
5/20 Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up [Seeking Alpha] 11.1%
4/15 Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit 9.2%
9/11 Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference 7.3%
12/31 Form 4 Outlook Therapeutics, For: Dec 31 Filed by: Pillai Arun Kumar 48.6%
2/24 Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market 20.0%
12/3 Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 16.9%
7/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 14.8%
12/30 Form 4 Outlook Therapeutics, For: Dec 23 Filed by: Pillai Arun Kumar 13.5%
12/23 Form 8-K Outlook Therapeutics, For: Dec 20 11.3%
5/20 Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up [Seeking Alpha] 11.1%
4/15 Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit 9.2%
9/11 Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference 7.3%
TOP News Decliners
12/23
Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions
-50.0%
1/28 Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 -15.0%
12/3 Outlook Therapeutics up 49% on advancement of ONS-5010 [Seeking Alpha] -14.0%
8/27 Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference -12.6%
5/15 Q2/2019 3/31/2019 EPS -0.580 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%
5/17 Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days [MarketWatch] -9.1%
9/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.0%
6/3 Form S-3 Outlook Therapeutics, -7.3%
2/24 Form 424B5 Outlook Therapeutics, -7.3%
6/14 Form 8-K Outlook Therapeutics, For: Jun 11 -7.3%
1/28 Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 -15.0%
12/3 Outlook Therapeutics up 49% on advancement of ONS-5010 [Seeking Alpha] -14.0%
8/27 Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference -12.6%
5/15 Q2/2019 3/31/2019 EPS -0.580 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%
5/17 Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days [MarketWatch] -9.1%
9/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.0%
6/3 Form S-3 Outlook Therapeutics, -7.3%
2/24 Form 424B5 Outlook Therapeutics, -7.3%
6/14 Form 8-K Outlook Therapeutics, For: Jun 11 -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: